The Life Raft Group is pleased to announce the release of the eighth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to [...]
By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought to [...]
Karen Darnell appreciates the value of life jackets. In her GIST journey, she recognizes the importance of having one constructed from the fabric of family support, GIST experts, email communities and the Life Raft Group. [...]
Dr. Sosipatros Boikos, a graduate of University of Crete in Greece, very early and while he was a first year medical student, developed an interest in cancer genetics. After graduating from medical school, he came to the National Institutes of Health as a Visiting Research Fellow to work on the genetics of Wildtype gastrointestinal stromal tumors—those GIST tumors without a KIT or PDGFRA mutation—under the supervision of Dr. Constantine Stratakis, the researcher who identified Carney-Stratakis Syndrome.
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent [...]
By Jonathan Fletcher, M.D. & Sebastian Buaer, M.D. Within the past decade, GISTs have emerged from being poorly defined, treatment-resistant tumors to a well recognized, well understood, and treatable tumor entity. Rapid advances in the understanding [...]
This is the eighth article in a series written by each of the key members of the LRG Resistance Research Team. Several articles in the LRG newsletter from our GIST Resistance Research Team have been [...]
This is the second of a two-part series on KIT and PDGFRA mutations in GISTs, written collaboratively by Drs. Michael Heinrich and Christopher Corless, LRG research team members. Please refer to the May issue of our newsletter for the first part titled, “KIT & PDGFRA mutations in GIST: A to Z” by Dr. Heinrich.
The ability of mutational analysis to predict the response of GIST tumors to Gleevec has been known since Dr. Charles Blanke’s GIST presentation at the plenary session of the 2001 American Society of Clinical Oncology [...]